SOHO 2023 | ICC guideline revisions for patients with MDS: improving diagnosis in MDS
Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, discusses guideline revisions for patients with myelodysplastic syndromes (MDS) aimed at increasing the precision of MDS diagnosis and providing clinicians with improved guidance. Dr Hasserjian comments on the addition of the MDS/acute myeloid leukemia (AML) entity by the International Consensus Classification (ICC). Dr Hasserjian also addresses the inclusion of additional genetic categories of MDS by the ICC and the World Health Organization (WHO), including lower-risk (LR)-MDS defined by SF3B1 mutation and aggressive disease defined by TP53 mutation. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
